October 16, 2023
3 min watch
Save
VIDEO: Rapid, sustained vision gains seen with treat-and-extend faricimab for DME
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this Healio Video Perspective, Yoshihiro Yonekawa, MD, discusses a presentation from the Retina Society meeting that evaluated the treat-and-extend cohort of the phase 3 YOSEMITE and RHINE trials.
The cohort included patients who received treat-and-extend faricimab for diabetic macular edema.
“We know how many [patients] made it to 12 and 16 weeks with faricimab, but our question was, how did those patients do in terms of vision and anatomy as we extended the intervals?” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Yonekawa Y. Faricimab treat-and-extend-based dosing dynamics in the phase 3 YOSEMITE/RHINE trials. Presented at: Retina Society meeting; Oct. 11-14, 2023; New York.
Disclosures:
Yonekawa reports consulting for Alcon, EyePoint and Versant Health and being a principal investigator for Genentech, Kodiak and Regeneron.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.